RANI earnings

- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Special Situations Funds, and Invus – - Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® – - Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 – - Initiated Phase 1 Study of RT-114 RaniPill® for the treatment of obesity in collaboration with ProGen

SAN JOSE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2025 and provide a business update on Thursday, March 26, 2026 after the close of trading. Rani's management team will host a conference call and webcast beginning at 4:30 p.m. ET. Conference Call and Webcast Rani Therapeutics will host a conference call and live webcast at 4:30 p.m. ET / 1:30 p.m. PT on March 26, 2026. Individuals interested in listen

- Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - - Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® capsule - - Preclinical data of four incretin-based molecules underscores the RaniPill® platform's potential to facilitate the oral delivery of a diverse array of obesity treatments - - Phase 1 study for RT-114 for the treatment of obesity, expected to initiate in mid-2025 - - Conference call today at 4:30 p.m. ET / 1:30 p.m. PT - SAN JOSE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Rani Therapeut

SAN JOSE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2024 and provide a business update on Monday, March 31, 2025 after the close of trading. Rani's management team will host a conference call and webcast beginning at 4:30 p.m. ET. Conference Call and Webcast Rani Therapeutics will host a conference call and live webcast at 4:30 p.m. ET / 1:30 p.m. PT on March 31, 2025. Individuals interested in listenin

~ New RT-114 obesity program combines ProGen's FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism with bioavailability comparable to subcutaneous injection ~ ~ Rani and ProGen to share responsibilities for the development and commercialization of RT-114, including a 50/50 cost and revenue share arrangement ~ ~ Rani to host conference call today at 8:00 a.m. ET/5:00 a.m. PT ~ SAN JOSE, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani")(NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and

- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Announced Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist - - Cash runway extended into 2025 - - Conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT - SAN JOSE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter and full year ended December 31, 2023 and provided a corporate update. "

SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 and provide a business update on Wednesday, March 20 after the close of trading. Rani's management team will host a conference call and webcast beginning at 4:30 p.m. ET. Conference Call and Webcast Rani Therapeutics will host a conference call and live webcast at 4:30 p.m. ET / 1:30 p.m. PT on March 20, 2024. Individuals interested in listening t

- RT-111 achieved high bioavailability in humans - - RT-111 was well-tolerated, with no serious adverse events - - Celltrion has right of first negotiation to acquire worldwide rights to RT-111 following a Phase 1 clinical trial that meets its primary endpoints – - Rani has now successfully completed three Phase 1 trials using RaniPill® technology - - Company to host conference call today at 8:30 a.m. ET / 5:30 a.m. PT – SAN JOSE, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced positive topline results

SAN JOSE, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2022 on Wednesday, March 22 after the close of trading. Rani's management team will host a conference call and webcast beginning at 4:30 p.m. ET. To access the call by phone, please use this registration link, and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahea

- RT-102 achieved all of its endpoints in the repeat-dose Part 2 of the Phase 1 Study - - Repeat doses of RT-102 were generally well tolerated, with no serious adverse events - - RaniPill™ GO delivered PTH to subjects with a 91% success rate and demonstrated high bioavailability - - Data from Part 1 and Part 2 of the Phase 1 study of RT-102 support advancement to a Phase 2 study – - Company to host conference call today at 4:30 pm ET / 1:30 pm PT - SAN JOSE, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announc

- Initiated a Phase 1 clinical trial of RT-102 for the potential treatment of osteoporosis - - Unveiled the high-capacity RaniPill™ HC, capable of delivering payloads of up to 20 mg - - Strengthened Board with the appointments of Lyn Baranowski and Lisa Rometty – - Conference call and webcast today at 4:30 p.m. ET - SAN JOSE, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update. "The year 2021 and

SAN JOSE, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company will release fourth quarter and full year 2021 financial results on Tuesday, March 29, 2022 after the close of market. Rani will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a business update. Individuals interested in listening to the live conference call may do so by dialing (844) 605-7369 for domestic callers, or (929) 517-0917 for international cal